Seven success stories of LSSSDC’s partnerships to fight COVID-19
Zydus Cadila, Cadila Pharma, Biocon, Syngene, Glenmark, Serum Institute of India, Ipca, Strides are using LSSSDC’s programmes to…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
Biocon’s partner Mylan receives favourable ruling from US PTAB on Sanofi’s four device patents for…
Reportedly, the PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.
Pharma leaders, policy makers discuss COVID-19 impact, way forward for industry
Most are optimistic about the future but accentuate the need for investments in technology and other strategic measures to ensure…
Biocon Biologics gets DCGI approval for emergency use of CytoSorb to treat critical COVID-19…
US FDA recently approved CytoSorb for emergency use in COVID-19 patients
Biocon Biologics receives EU GMP Certification for multiple Biosimilars manufacturing facilities in…
These facilities are used for the manufacture of DS and DP for Biosimilars: Bevacizumab, Trastuzumab, Pegfilgrastim and secondary…
Biocon registers a 42 per cent dip in profits for Q4
The company also reported a 15 per cent increase in EBITDA at Rs 1,765 Cr
EU GMP Certification for Biocon Biologics Drug Substance Facilities in Bengaluru
These facilities were inspected by the regulatory agency between January 20 and 23, 2020
Biocon receives EIR for its Bommansandra facility
The inspection was carried out from January 20-24, 2020
Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in…
The Medicine Maker ‘Power List 20 for 2020’ celebrates 60 great minds who have brought the world innovation in small molecules,…
Biocon and Mylan launch fulphila — biosimilar to pegfilgrastim, in Canada
The approval of fulphila was based on a comprehensive package of analytical, non-clinical and clinical data, which confirmed that…